Iodine Deficiency and Mortality in Spanish Adults: Di@bet.es Study
Por:
Maldonado-Araque, C, Valdes, S, Badia-Guillen, R, Lago-Sampedro, A, Colomo, N, Garcia-Fuentes, E, Gutierrez-Repiso, C, Goday, A, Calle-Pascual, A, Castano, L, Castell, C, Delgado, E, Menendez, E, Franch-Nadal, J, Gaztambide, S, Girbes, J, Chaves, F, Soriguer, F and Rojo-Martinez, G
Publicada:
1 ene 2021
Ahead of Print:
1 sep 2020
Resumen:
Background:Longitudinal data assessing the impact of iodine deficiency (ID) on mortality are scarce. We aimed to study the association between the state of iodine nutrition and the risk of total and cause-specific mortality in a representative sample of the Spanish adult population. Methods:We performed a longitudinal observational study to estimate mortality risk according to urinary iodine (UI) concentrations using a sample of 4370 subjects >18 years representative of the Spanish adult population participating in the nationwide study Di@bet.es (2008-2010). We used Cox regression to assess the association between UI at the start of the study (<50, 50-99, 100-199, 200-299, and >= 300 mu g/L) and mortality during follow-up (National death registry-end of follow-up December 2016) in raw models, and adjusted for possible confounding variables: age, sex, educational level, hypertension, diabetes, obesity, chronic kidney disease, smoking, hypercholesterolemia, thyroid dysfunction, diagnosis of cardiovascular disease or cancer, area of residence, physical activity, adherence to Mediterranean diet, dairy and iodinated salt intake. Results:A total of 254 deaths were recorded during an average follow-up period of 7.3 years. The causes of death were cardiovascular 71 (28%); cancer 85 (33.5%); and other causes 98 (38.5%). Compared with the reference category with adequate iodine nutrition (UI 100-300 mu g/L), the hazard ratios (HRs) of all-cause mortality in the category with UI >= 300 mu g/L were 1.04 (95% confidence interval [CI 0.54-1.98]); however, in the categories with 50-99 UI and <50 mu g/L, the HRs were 1.29 [CI 0.97-1.70] and 1.71 [1.18-2.48], respectively (pfor trend 0.004). Multivariate adjustment did not significantly modify the results. Conclusions:Our data indicate an excess mortality in individuals with moderate-severe ID adjusted for other possible confounding factors.
Filiaciones:
Maldonado-Araque, C:
Hosp Reg Univ Malaga, Inst Invest Biomed Malaga IBIMA, Dept Endocrinol & Nutr, Malaga, Spain
Inst Salud Carlos III, Ctr Invest Biomed Red Diabet & Enfermedades Metab, Madrid, Spain
Valdes, S:
Hosp Reg Univ Malaga, Inst Invest Biomed Malaga IBIMA, Dept Endocrinol & Nutr, Malaga, Spain
Inst Salud Carlos III, Ctr Invest Biomed Red Diabet & Enfermedades Metab, Madrid, Spain
Badia-Guillen, R:
Hosp Reg Univ Malaga, Inst Invest Biomed Malaga IBIMA, Dept Endocrinol & Nutr, Malaga, Spain
Lago-Sampedro, A:
Hosp Reg Univ Malaga, Inst Invest Biomed Malaga IBIMA, Dept Endocrinol & Nutr, Malaga, Spain
Inst Salud Carlos III, Ctr Invest Biomed Red Diabet & Enfermedades Metab, Madrid, Spain
Colomo, N:
Hosp Reg Univ Malaga, Inst Invest Biomed Malaga IBIMA, Dept Endocrinol & Nutr, Malaga, Spain
Inst Salud Carlos III, Ctr Invest Biomed Red Diabet & Enfermedades Metab, Madrid, Spain
Garcia-Fuentes, E:
Hosp Univ Virgen Victoria, Inst Invest Biomed Malaga IBIMA, UGC Aparato Digest, Malaga, Spain
Gutierrez-Repiso, C:
Inst Salud Carlos III, Ciber Fisiopatol Obesidad & Nutr CIBEROBN, Madrid, Spain
Hosp Univ Virgen Victoria, Inst Invest Biomed Malaga IBIMA, Dept Endocrinol & Nutr, Malaga, Spain
Goday, A:
Hosp del Mar, Dept Endocrinol & Nutr, Barcelona, Spain
Calle-Pascual, A:
Inst Salud Carlos III, Ctr Invest Biomed Red Diabet & Enfermedades Metab, Madrid, Spain
Hosp Univ S Carlos Madrid, Dept Endocrinol & Nutr, Madrid, Spain
Castano, L:
Inst Salud Carlos III, Ctr Invest Biomed Red Diabet & Enfermedades Metab, Madrid, Spain
Univ Basque Country, BioCruces Bizkaia, Hosp Univ Cruces, Baracaldo, Spain
Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Raras CIBERER, Madrid, Spain
Castell, C:
Publ Hlth Agcy Catalonia, Dept Hlth, Barcelona, Spain
Delgado, E:
Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Raras CIBERER, Madrid, Spain
Univ Oviedo, Inst Invest Sanitaria Principado Asturias ISPA, Hosp Univ Cent Asturias, Dept Endocrinol & Nutr, Oviedo, Spain
Menendez, E:
Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Raras CIBERER, Madrid, Spain
Univ Oviedo, Inst Invest Sanitaria Principado Asturias ISPA, Hosp Univ Cent Asturias, Dept Endocrinol & Nutr, Oviedo, Spain
Franch-Nadal, J:
Inst Salud Carlos III, Ctr Invest Biomed Red Diabet & Enfermedades Metab, Madrid, Spain
Inst Catala Salut, EAP Raval Sud, Unitat Suport Recerca, Primary Care,Fundacio Jordi Gol,IDIAP,Red GEDAPS, Barcelona, Spain
Gaztambide, S:
Inst Salud Carlos III, Ctr Invest Biomed Red Diabet & Enfermedades Metab, Madrid, Spain
Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Raras CIBERER, Madrid, Spain
Univ Basque Country, BioCruces Bizkaia, Hosp Univ Cruces, Dept Endocrinol & Nutr, Baracaldo, Spain
:
Hosp Arnau Vilanova, Diabet Unit, Valencia, Spain
Chaves, F:
Inst Salud Carlos III, Ctr Invest Biomed Red Diabet & Enfermedades Metab, Madrid, Spain
Fundacio Invest Hosp Clin Valencia INCLIVA, Genom Studies & Genet Diag Unit, Valencia, Spain
Soriguer, F:
Hosp Reg Univ Malaga, Inst Invest Biomed Malaga IBIMA, Dept Endocrinol & Nutr, Malaga, Spain
Inst Salud Carlos III, Ctr Invest Biomed Red Diabet & Enfermedades Metab, Madrid, Spain
Rojo-Martinez, G:
Hosp Reg Univ Malaga, Inst Invest Biomed Malaga IBIMA, Dept Endocrinol & Nutr, Malaga, Spain
Inst Salud Carlos III, Ctr Invest Biomed Red Diabet & Enfermedades Metab, Madrid, Spain
Green Published, Green Submitted, hybrid
|